IL6 and myasthenia gravis: Targeting IL-6 to inhibit B cell proliferation and activation, the monoclonal antibody satralizumab (phase III LUMINESCE trial completed in 2024, preliminary results published (163), NCT04963270) and tocilizumab (ongoing phase II trial, NCT05067348) may also have therapeutic potential in MuSK-MG.